The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease

2009 ◽  
Vol 24 (5) ◽  
pp. 762-766 ◽  
Author(s):  
Julia Vaamonde ◽  
José M. Flores ◽  
Roberto Weisser ◽  
Ramón Ibañez ◽  
José A. Obeso
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response

THUR 117 The L-DOPA response in pathologically confirmed parkinson’s disease

2018 ◽  
Vol 89 (10) ◽  
pp. A12.4-A13
Author(s):  
Vanessa Pitz ◽  
Naveed Malek ◽  
Katherine A Grosset ◽  
Donald G Grosset
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response ◽  
Standard Treatment ◽  
Disease Onset ◽  
Lewy Body Disease ◽  
Amyloid Angiopathy ◽  
Brain Pathology ◽  
Diffuse Lewy Body Disease ◽  
Available Information

Backgroundl-dopa is the standard treatment for Parkinson’s disease, but the response is variable.AimSystematic review of papers reporting the l-dopa response (motor response and/or complications) in pathologically confirmed Parkinson’s disease.Results467 cases of pathologically confirmed Parkinson’s were identified: 60.2% male, age at disease onset 63.3 years (SD 10.3), age at death 76.7 years (SD 7.8). Data on a graded l-dopa response were available in 411 cases (88.0% of 467). The motor response was excellent in 148/411 cases (36.0%), good in 179/411 (43.6%), moderate in 51/411 (12.4%) and poor/absent in 33/411 (8.0%). Data about motor complications were available for 161 patients: 71/161 (44.1%) had motor fluctuations and 89/161 (55.3%) had dyskinesia. Comorbid brain pathology was evaluated in 251/411 cases (61.1%), and was present in 148/251 (59.0%): cerebrovascular in 65/148 (43.9%), Alzheimer’s in 55/148 (37.2%), amyloid angiopathy in 18/148 (12.2%), and diffuse Lewy body disease in 10/148 (6.8%). Data linking the graded l-dopa response to comorbid pathologies were available in only 17 cases, of whom 8/17 (47.1%) had a good/excellent response.ConclusionThere is variation in the l-dopa response in pathologically confirmed Parkinson’s disease. The limited available information suggests a possible association of motor response to comorbid brain pathology.

Longitudinal study of the motor response to levodopa in Parkinson's disease

2006 ◽  
Vol 21 (12) ◽  
pp. 2116-2121 ◽  
Author(s):  
Benjamin G. Clissold ◽  
Craig D. McColl ◽  
Katrina R. Reardon ◽  
Mark Shiff ◽  
Peter A. Kempster
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Longitudinal Study ◽  
Motor Response

Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease

2002 ◽  
Vol 17 (6) ◽  
pp. 1227-1234 ◽  
Author(s):  
Craig D. McColl ◽  
Katrina A. Reardon ◽  
Mark Shiff ◽  
Peter A. Kempster
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response ◽  
Motor Fluctuations

CNV potential and motor response in Parkinson’s disease patients

2008 ◽  
Vol 119 (3) ◽  
pp. e72-e73
Author(s):  
J. Pluncevic Gligoroska ◽  
L. Bozinovska ◽  
S. Mancevska ◽  
E. Sivevska
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response

Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease

Neurology ◽  
1996 ◽  
Vol 46 (4) ◽  
pp. 1055-1058 ◽  
Author(s):  
M. Contin ◽  
R. Riva ◽  
P. Martinelli ◽  
E.J. Triggs ◽  
F. Albani ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Motor Response ◽  
Clinical Progression

scholarly journals Deep Brain Stimulation and Treatment Outcomes of Young- and Late-Onset (≤55 Years) Parkinson's Disease: A Population-Based Study

2021 ◽  
Vol 12 ◽  
Author(s):  
Emanuele Camerucci ◽  
Cole D. Stang ◽  
Pierpaolo Turcano ◽  
Philip W. Tipton ◽  
James H. Bower ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Brain Stimulation ◽  
Motor Response ◽  
Late Onset ◽  
Poor Response ◽  
Population Based ◽  
Motor Complications ◽  
Deep Brain

Background: No studies have reported the rate of motor complications (MC) and response to medical and surgical treatment in a population-based cohort of young-onset Parkinson's Disease (YOPD) patients and a cohort of sex-matched late-onset Parkinson's Disease (LOPD).Objective: To assess the outcomes of dopaminergic treatment in YOPD and LOPD, explore treatment-induced MC, medical adjustment, and rate of deep brain stimulation (DBS).Methods: We used the expanded Rochester Epidemiology Project (eREP) to investigate a population-based cohort of YOPD between 2010 and 2015 in 7 counties in Minnesota. Cases with onset ≤55 years of age were included as YOPD. An additional sex-matched cohort of LOPD (onset at ≥56 years of age) was included for comparison. All medical records were reviewed to confirm the diagnoses.Results: In the seven counties 2010–15, there were 28 YOPD patients, which were matched with a LOPD cohort. Sixteen (57%) YOPD had MC, as compared to 9 (32%) LOPD. In YOPD, 9 had motor fluctuations (MF) and Levodopa-induced dyskinesia (LID) together, whereas 3 had LID only and 4 MF only. In LOPD, 3 had MF and LID, 3 MF only, and 3 LID only. Following medical treatment for MC, 6/16 YOPD (38%) and 3/9 (33%) LOPD had symptoms resolution. In YOPD, 11/16 (69%) were considered for DBS implantation, in LOPD they were 2/9 (22%), but only 7 (6 YOPD and 1 LOPD) underwent the procedure. YOPD had significantly higher rates in both DBS candidacy and DBS surgery (respectively, p = 0.03 and p = 0.04). Among DBS-YOPD, 5/6 (83%) had positive motor response to the surgery; the LOPD case had a poor response. We report the population-based incidence of both YOPD with motor complications and YOPD undergoing DBS, which were 1.17 and 0.44 cases per 100,000 person-years, respectively.Conclusion: Fifty-seven percent of our YOPD patients and 32% of the LOPD had motor complications. Roughly half of both YOPD and LOPD were treatment resistant. YOPD had higher rates of DBS candidacy and surgery. Six YOPD and 1 LOPD underwent DBS implantation and most of them had a positive motor response after the surgery.

Sign in / Sign up

Export Citation Format

Share Document